| (210) | Number of the EPO application | 18821779 |
| (220) | Filing date of the EPO application | 2018.11.21 |
| (80) | EPO patent specification publication (B) | EPB nr. 31/2023, 2023.08.02 |
| (110) | EPO patent number | 3713919 |
| (11) | Number of the document | MD 3713919 T2 |
| (21) | Number of the application | e 2020 0988 |
| (71) | Name(s) of applicant(s), code of the country | AGIOS PHARMACEUTICALS, INC., US; |
| (72) | Name(s) of inventor(s), code of the country | SIZEMORE Jacob P., US;
GUO Liting, CN;
MIRMEHRABI Mahmoud, CA;
SU Yeqing, CA; |
| (73) | Name(s) of owner(s), code of the country | AGIOS PHARMACEUTICALS INC., US; |
| (54) | Title of the invention | Crystalline forms of N-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07D 215/36 (2006.01.01); A61P 7/06 (2006.01.01); A61K 31/4709 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2020.10.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2024.02.29 |
| (30) | Priority | 201762589822 P, 2017.11.22, US; 201862691709 P, 2018.06.29, US |
| (74) | Patent attorney | (Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova |
| (86) | International application | PCT/US2018/062197, 2018.11.21 |
| (87) | International publication | WO 2019/104134, 2019.05.31 |